Nomura Asset Management Co. Ltd. Sells 10,047 Shares of Amgen Inc. $AMGN

Nomura Asset Management Co. Ltd. reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 3.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 299,167 shares of the medical research company’s stock after selling 10,047 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Amgen were worth $97,920,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of AMGN. Robeco Institutional Asset Management B.V. boosted its holdings in Amgen by 10.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after purchasing an additional 43,884 shares during the period. Curtis Advisory Group LLC bought a new stake in Amgen in the 4th quarter valued at $1,669,000. Jones Financial Companies Lllp boosted its holdings in Amgen by 18.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock valued at $10,888,000 after purchasing an additional 6,115 shares during the period. Adell Harriman & Carpenter Inc. boosted its holdings in Amgen by 7.9% in the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after purchasing an additional 1,609 shares during the period. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Amgen in the 4th quarter valued at $22,441,000. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on AMGN shares. Canaccord Genuity Group started coverage on shares of Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 price target for the company. Citigroup increased their price target on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Guggenheim reduced their price target on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a report on Monday, May 4th. Daiwa Securities Group dropped their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. Finally, Jefferies Financial Group assumed coverage on shares of Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus price target of $355.19.

Amgen Trading Up 0.1%

Shares of AMGN stock opened at $336.79 on Friday. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29. The stock has a market cap of $181.77 billion, a price-to-earnings ratio of 23.44, a P/E/G ratio of 3.38 and a beta of 0.44. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The firm has a fifty day moving average of $342.53 and a 200-day moving average of $345.33.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same quarter in the prior year, the company posted $4.90 EPS. The business’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts forecast that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. Amgen’s dividend payout ratio (DPR) is 70.15%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.85% of the stock is owned by company insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.